Showing 1 - 3 results of 3 for search 'Ajay Nirula', query time: 0.01s Refine Results
  1. 1
    Serum IL-6 and PTX3 predict severe outcome from COVID-19 in ambulatory subjects: Impact for future therapeutic decisions.

    Serum IL-6 and PTX3 predict severe outcome from COVID-19 in ambulatory subjects: Impact for future therapeutic decisions. by Josh Poorbaugh, Jonathan T Sims, Lin Zhang, Ching-Yun Chang, Richard E Higgs, Ajay Nirula, Robert J Benschop

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Ucenprubart is an agonistic antibody to CD200R with the potential to treat inflammatory skin disease: preclinical development and a phase 1 clinical study

    Ucenprubart is an agonistic antibody to CD200R with the potential to treat inflammatory skin disease: preclinical development and a phase 1 clinical study by Anja Koester, Derrick R. Witcher, Mark Lee, Stephen J. Demarest, Scott Potter, Katie Werle, Scott Bauer, Diana Ruiz, Laurent Malherbe, Josh Poorbaugh, Andrew Glasebrook, Christoph Preuss, Gourab Datta, Ziqiao Wang, Jack Knorr, David Manner, Dipak Patel, Carsten Schmitz, Paul Klekotka, Ajay Nirula

    Published 2025-05-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Mechanism of baricitinib supports artificial intelligence‐predicted testing in COVID‐19 patients

    Mechanism of baricitinib supports artificial intelligence‐predicted testing in COVID‐19 patients by Justin Stebbing, Venkatesh Krishnan, Stephanie de Bono, Silvia Ottaviani, Giacomo Casalini, Peter J Richardson, Vanessa Monteil, Volker M Lauschke, Ali Mirazimi, Sonia Youhanna, Yee‐Joo Tan, Fausto Baldanti, Antonella Sarasini, Jorge A Ross Terres, Brian J Nickoloff, Richard E Higgs, Guilherme Rocha, Nicole L Byers, Douglas E Schlichting, Ajay Nirula, Anabela Cardoso, Mario Corbellino, the Sacco Baricitinib Study Group

    Published 2020-06-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: